INCY - CIK 0000879169
INCYTE CORP trades as INCY and has a market capitalization of $21.23 B, making it the #595 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $5.14B, up 21.2% from the prior year and net income of $1.29B. This page tracks INCYTE CORP through 2,536 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years INCYTE CORP's revenue grew from $1.11B to $5.14B, a compound annual growth rate of 18.6%. Net profit margin expanded from 9.4% to 25.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade (amended) | 4/A | 2026-05-20 |
| Insider trade (amended) | 4/A | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-11 |
| SCHEDULE 13D/A | - | 2026-05-11 |
| Insider trade | 4 | 2026-05-06 |
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work.
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium
The largest companies sharing INCYTE CORP's SEC industry classification (services-commercial physical & biological research).
INCYTE CORP (INCY) has a market capitalization of $21.23 B as of 2026-06-10, ranking #595 among US-listed companies.
INCYTE CORP reported revenue of $5.14B for fiscal year 2025, an increase of 21.2% year over year.
Yes. INCYTE CORP reported net income of $1.29B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.